Rational combination therapies for JAK-driven haematological malignancies

Lead researcher

Dr Michaela Waibel, Prof Ricky Johnstone, Prof John Seymour

Cancer Therapeutics Program, Peter MacCallum Cancer Centre

Years funded

Our research focuses on novel combination therapies for haematological cancers driven by activation of particular cell survival pathways. We investigate how certain genetic changes promote the survival of cancer cells, and how these cancer cells become resistant to drug treatment. This will allow us to develop novel potent combination therapies for the treatment of acute leukaemia and myeloproliferative neoplasms, and to overcome drug-resistance to improve the outcomes for patients.

Funding Body

Cancer Council Research Grant


$99,805 per annum